Advertisement
UK markets closed
  • FTSE 100

    8,145.36
    +66.50 (+0.82%)
     
  • FTSE 250

    19,820.80
    +218.82 (+1.12%)
     
  • AIM

    755.30
    +2.18 (+0.29%)
     
  • GBP/EUR

    1.1664
    +0.0008 (+0.07%)
     
  • GBP/USD

    1.2467
    -0.0044 (-0.35%)
     
  • Bitcoin GBP

    50,831.27
    -402.09 (-0.78%)
     
  • CMC Crypto 200

    1,321.20
    -75.34 (-5.16%)
     
  • S&P 500

    5,098.93
    +50.51 (+1.00%)
     
  • DOW

    38,208.92
    +123.12 (+0.32%)
     
  • CRUDE OIL

    84.08
    +0.51 (+0.61%)
     
  • GOLD FUTURES

    2,345.10
    +2.60 (+0.11%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,164.57
    +247.29 (+1.38%)
     
  • CAC 40

    8,092.49
    +75.84 (+0.95%)
     

Should Income Investors Buy This Soon-to-Be Dividend King?

Should Income Investors Buy This Soon-to-Be Dividend King?

Imagine spending a lifetime building your investment portfolio only to worry about whether you will outlive the balance in your investment accounts. If you are exclusively buying growth stocks with the intent of eventually selling them off for capital gains to sustain your lifestyle, running out of money could be a possibility. Consider medical device maker Medtronic (NYSE: MDT).